NASH: how non-invasive biomarkers promise to displace biopsies

Non-invasive biomarkers in NASH are beginning to show where and how they can upstage liver biopsies, with the first impact appearing in patient recruitment. The biggest value will come when they can serve as regulatory endpoints, allowing for shorter trials that cost less and spare patients unwelcome procedures.

Liver biopsies have been a mainstay in non-alcoholic steatohepatitis (NASH), where they are used for histological assessment of changes from baseline in fat accumulation, inflammation and fibrosis. ...